DCC-3116 is under clinical development by Deciphera Pharmaceuticals and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to GlobalData, Phase II drugs for Gastrointestinal Stromal Tumor (GIST) have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DCC-3116’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DCC-3116 overview
DCC-3116 is under development for the treatment of mutated RAS and RAF mutant advanced or metastatic solid tumors including gastrointestinal stromal tumor, non-small cell lung cancer. The drug candidate acts by targeting ULK1/2 and is developed based on switch control inhibitor platform. It is administered orally as a tablet.
It was under treatment for pancreatic ductal adenocarcinoma, colorectal cancer and melanoma.
Deciphera Pharmaceuticals overview
Deciphera Pharmaceuticals is a research and development company that develops, designs and commercializes kinase-inhibiting drugs. The company provides a clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses a proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals pipeline products include ripretinib, vimseltinib, DCC-3009, DCC-3116 and DCC-3084 treat renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, Crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.
For a complete picture of DCC-3116’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
